Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts
- PMID: 24566711
- DOI: 10.1038/bmt.2014.12
Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts
Abstract
Mobilized peripheral blood (mPB) is a prevalent source of hematopoietic progenitors for transplantation; however, allogeneic and haploidentical transplants are often accompanied by severe GVHD. Following the observation that murine GVHD is ameliorated by pretransplant donor cell exposure to Fas-ligand (FasL) without host-specific sensitization, we assessed the susceptibility of mPB cells to spontaneous and receptor-induced apoptosis as a possible approach to GVHD prophylaxis. Short incubation for 4 h resulted in spontaneous apoptosis of 50% of the T and B lymphocytes and 60% myeloid cells. Although expression of Fas and TNF-R1 was proportionate to fractional apoptosis, cell death was dominated by spontaneous apoptosis. Functional assays revealed that the death receptors modulated mPB graft composition as compared with incubation in medium, without detectable quantitative variations. Removal of dead cells increased the frequency of mPB myeloid progenitors (P<0.001 vs medium), and recipients of mPB exposed to death ligands displayed reduced GVHD (P<0.01 vs medium) and improved survival following lipopolysacharide stimulation. mPB grafts exposed to the apoptotic challenge retained SCID reconstituting potential and graft versus tumor activity. These data emphasize that short-term exposure of mPB grafts to an apoptotic challenge is effective in reduction of GVHD effector activity.
Similar articles
-
Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.Biol Blood Marrow Transplant. 2013 Feb;19(2):185-95. doi: 10.1016/j.bbmt.2012.10.004. Epub 2012 Oct 16. Biol Blood Marrow Transplant. 2013. PMID: 23078782
-
Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.Front Immunol. 2018 Dec 19;9:2979. doi: 10.3389/fimmu.2018.02979. eCollection 2018. Front Immunol. 2018. PMID: 30631325 Free PMC article. Review.
-
Regulatory T Cell Amelioration of Graft-versus-Host Disease following Allogeneic/Xenogeneic Hematopoietic Stem Cell Transplantation Using Mobilized Mouse and Human Peripheral Blood Donors.Transplant Cell Ther. 2023 May;29(5):341.e1-341.e9. doi: 10.1016/j.jtct.2023.02.015. Epub 2023 Feb 18. Transplant Cell Ther. 2023. PMID: 36804930 Free PMC article.
-
Investigation into an engraftment defect induced by culturing primitive hematopoietic cells with cytokines.Cytotherapy. 2001;3(4):307-20. doi: 10.1080/146532401317070943. Cytotherapy. 2001. PMID: 12171719
-
Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.Int Immunopharmacol. 2003 Aug;3(8):1121-43. doi: 10.1016/S1567-5769(03)00014-6. Int Immunopharmacol. 2003. PMID: 12860168 Review.
Cited by
-
A DL-4- and TNFα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors.Cell Mol Immunol. 2021 Jul;18(7):1662-1676. doi: 10.1038/s41423-021-00706-8. Epub 2021 Jun 11. Cell Mol Immunol. 2021. PMID: 34117371 Free PMC article.
-
Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers.Front Immunol. 2020 Jun 25;11:1338. doi: 10.3389/fimmu.2020.01338. eCollection 2020. Front Immunol. 2020. PMID: 32670295 Free PMC article. Review.
-
Negative selection by apoptosis enriches progenitors in naïve and expanded human umbilical cord blood grafts.Bone Marrow Transplant. 2014 Jul;49(7):942-9. doi: 10.1038/bmt.2014.79. Epub 2014 Apr 28. Bone Marrow Transplant. 2014. PMID: 24777188
-
Treatment with Mesenchymal Stromal Cells Overexpressing Fas-Ligand Ameliorates Acute Graft-versus-Host Disease in Mice.Int J Mol Sci. 2022 Jan 4;23(1):534. doi: 10.3390/ijms23010534. Int J Mol Sci. 2022. PMID: 35008964 Free PMC article.
-
Antigen-Specific Priming is Dispensable in Depletion of Apoptosis-Sensitive T Cells for GvHD Prophylaxis.Front Immunol. 2014 May 19;5:215. doi: 10.3389/fimmu.2014.00215. eCollection 2014. Front Immunol. 2014. PMID: 24904571 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous